Home
    Disclaimer
    ← Back to MDAI
    MDAI molecular structure

    MDAI Stats & Data

    Psychedelic Stimulant Empathogen Research-chemical
    Mindy Sparkle
    NPS DataHub
    MW177.2
    FormulaC10H11NO2
    CAS132741-81-2
    IUPAC6,7-Dihydro-5''H''-cyclopenta[''f''] [1,3]benzodioxol-6-amine
    SMILESNC1Cc2cc3OCOc3cc2C1
    InChIKeyFQDRMHHCWZAXJM-UHFFFAOYSA-N
    Phenethylamines; Aminoindanes; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Psychoactive Class Psychedelic / Stimulant

    Interaction Warnings

    ⚠ mdma

    The neurotoxic effects of MDMA may be increased when combined with other stimulants.

    ⚠ cocaine

    This combination may increase strain on the heart.

    Receptor Profile

    Receptor Actions

    Inhibitors
    Selective serotonin reuptake inhibitor (SSRI)
    Other
    Selective serotonin releasing agent (SSRA)
    Minor norepinephrine releasing agent

    Effect Profile

    Curated + 67 Reports
    Psychedelic 4.0

    Strong body load and auditory effects with moderate visuals, low headspace

    Visual Intensity×3
    67.91.0
    Headspace Depth×3
    24.61.4
    Auditory Effects×1
    810
    Body Load / Somatic Effects×1
    10101.7
    Catalog Erowid BlueLight
    Empathogen 9.7

    Strong empathy, euphoria, sensory enhancement, and stimulation

    Empathy / Social Openness×3
    10104.8
    Euphoria / Mood Elevation×2
    109.77.3
    Stimulation×1
    87.97.9
    Sensory Enhancement×1
    10103.5
    Catalog Erowid BlueLight
    Stimulant 7.5

    Strong euphoria and stimulation with moderate anxiety/jitters, mild focus

    Stimulation / Energy×3
    98.5
    Euphoria / Mood Lift×2
    108.1
    Focus / Productivity×2
    54.4
    Anxiety / Jitters×1
    710
    Catalog Erowid
    Based on reports from:
    Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki MDAI The Drug Users Bible MDAI

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Experience Report Analysis

    Erowid BlueLight
    41 Reports
    2010–2015 Date Range
    39 With Age Data
    26 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 67 experience reports (41 Erowid + 26 Bluelight)

    67 Reports
    105 Effects Detected
    45 Positive
    38 Adverse
    22 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 45

    Euphoria 65.7% 88%
    Stimulation 50.7% 81%
    Sociability Enhancement 50.0% 83%
    Music Enhancement 41.8% 91%
    Empathy 40.3% 87%
    Tactile Enhancement 32.8% 80%
    Love 30.8% 84%
    Body High 29.9% 78%
    Libido Enhancement 26.9% 81%
    Contentment 23.1% 82%
    Color Enhancement 20.9% 82%
    Joy 19.2% 85%
    Focus Enhancement 16.5% 75%
    Introspection 11.9% 78%
    Emotional Openness 11.5% 85%
    Morphing 7.7% 82%
    Communication Enhancement 7.7% 82%
    Depersonalization 7.7% 85%
    Thought Disorganization 7.7% 78%
    Memory Enhancement 7.7% 78%

    Adverse Effects 38

    Insomnia 34.6% 82%
    Anxiety 29.8% 82%
    Confusion 26.8% 70%
    Pupil Dilation 23.9% 86%
    Jaw Clenching 23.9% 80%
    Nausea 19.4% 72%
    Body Temperature Change 19.2% 75%
    Increased Heart Rate 17.1% 70%
    Dry Mouth 15.4% 82%
    Dysphoria 15.4% 81%
    Headache 13.4% 77%
    Sweating 11.9% 80%
    Muscle Tension 8.9% 75%
    Body Load 7.7% 75%
    Temperature Sensitivity 7.7% 78%
    Ataxia 7.7% 78%
    Fear 7.7% 92%
    Panic 7.7% 92%
    Thought Loops 7.7% 80%
    Dizziness 7.7% 80%

    Dose-Response Correlation

    How effect frequency changes across dose levels

    View data table
    Effect Common (n=12) Strong (n=15)
    Empathy 75.0% 40.0%
    Tactile Enhancement 66.7% 40.0%
    Music Enhancement 58.3% 53.3%
    Sedation 58.3% 26.7%
    Euphoria 50.0% 53.3%
    Body High 50.0% 13.3%
    Stimulation 50.0% 40.0%
    Anxiety 41.7% 33.3%
    Visual Distortions 33.3% 20.0%
    Focus Enhancement 33.3% 26.7%
    Nausea 33.3% 20.0%
    Jaw Clenching 33.3% 26.7%
    Sweating 33.3% 0%
    Color Enhancement 25.0% 33.3%
    Confusion 16.7% 33.3%

    Dose–Effect Mapping

    Experience Reports

    How reported effects shift across dose tiers, based on 41 experience reports.

    Limited tier coverage — most reports fall within the Common / Strong range. Effects at other dose levels may not be represented.

    Oral dose range: 100.0–200.0 mg (median 175.0 mg)
    Effect Common (n=12) Strong (n=15)
    empathy
    75%
    40%
    		↓
    tactile enhancement
    67%
    40%
    		↓
    music enhancement
    58%
    53%
    		→
    sedation
    58%
    27%
    		↓
    euphoria
    50%
    53%
    		→
    body high
    50%
    13%
    		↓
    stimulation
    50%
    40%
    		↓
    anxiety
    42%
    33%
    		↓
    visual distortions
    33%
    20%
    		↓
    focus enhancement
    33%
    27%
    		↓
    nausea
    33%
    20%
    		↓
    jaw clenching
    33%
    27%
    		↓
    sweating
    33%
    		— →
    color enhancement
    25%
    33%
    		↑
    confusion
    17%
    33%
    		↑
    pupil dilation
    17%
    27%
    		↑
    increased heart rate
    25%
    20%
    		↓
    muscle tension —
    20%
    		→
    closed-eye visuals
    17%
    		— →
    introspection
    17%
    		— →

    Showing top 20 of 22 effects

    Risk Escalation

    Sentiment Analysis

    Average frequency of positive vs adverse effects across dose tiers

    Common n=12
    9 positive 47.2% 8 adverse 27.1%
    Strong n=15
    8 positive 37.5% 7 adverse 25.7%
    View effect breakdown

    Adverse Effects

    Effect Common (n=12) Strong (n=15) Change
    Anxiety
    42%
    33%
    		-20%
    Nausea
    33%
    20%
    		-39%
    Jaw Clenching
    33%
    27%
    		-19%
    Sweating
    33%
    		— 0%
    Confusion
    17%
    33%
    		+99%
    Pupil Dilation
    17%
    27%
    		+59%
    Increased Heart Rate
    25%
    20%
    		-20%
    Muscle Tension —
    20%
    		0%
    Motor Impairment
    17%
    		— 0%

    Positive Effects

    Effect Common (n=12) Strong (n=15) Change
    Empathy
    75%
    40%
    		-46%
    Tactile Enhancement
    67%
    40%
    		-40%
    Music Enhancement
    58%
    53%
    		-8%
    Euphoria
    50%
    53%
    		6%
    Body High
    50%
    13%
    		-73%
    Stimulation
    50%
    40%
    		-20%
    Focus Enhancement
    33%
    27%
    		-19%
    Color Enhancement
    25%
    33%
    		+33%
    Introspection
    17%
    		— 0%

    Dosage Distribution

    Dose distribution from experience reports

    Median: 175.0 mg IQR: 100.0–200.0 mg n=28

    Real-World Dose Distribution

    62K Doses

    From 70 individual dose entries

    Oral (n=54)

    Median: 145.0mg 25th: 100.0mg 75th: 200.0mg 90th: 241.0mg
    mg/kg median: 1.948 mg/kg 75th: 2.564

    Insufflated (n=13)

    Median: 45.0mg 25th: 25.0mg 75th: 50.0mg 90th: 95.0mg
    mg/kg median: 0.616 mg/kg 75th: 0.909

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Median: 2.155 mg/kg IQR: 1.471–2.451 mg/kg n=26

    Redose Patterns

    Redosing behavior across 36 reports

    55.6% Redosed
    1.9 Avg Doses
    60m Median Interval
    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Austria MDAI is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
    Brazil MDAI is illegal to possess, produce and sell under Portaria SVS/MS nº 344.
    China As of October 2015 MDAI is a controlled substance in China.
    Denmark MDAI is illegal in Denmark as of September 2015.
    Finland Scheduled in the "government decree on psychoactive substances banned from the consumer market".
    Germany MDAI is controlled under the NpSG ( New Psychoactive Substances Act ) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
    Japan MDAI is a controlled substance in Japan effective March 30th, 2013.
    Switzerland As of December 2011 MDAI is a controlled substance in Switzerland.
    United Kingdom MDAI is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
    United States legal Caution : All legal information should be verified through other sources. see below U.S. FEDERAL LEGAL SUMMARY MDAI - REGULATED: No - STATUS: Not Approved ForHuman Consumption - SCHEDULE: Un-Scheduled MDAI is uncontrolled in the United States under federal law. This means it is generally considered legal to buy, possess, and distribute (sell, trade or give). If sold as a supplement, sales must conform to U.S. supplement laws. If sold for consumption as a food or drug, sales are regulated by the FDA. It is possible that it would be considered an analog in which case, sales for human consumption or possession with the intent to ingest could be prosecuted under the Federal Analogue Act or state analog acts. U.S. STATE LAW

    References

    Data Sources

    Cited References

    ← Back to MDAI